Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product’s patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
This report contains market size and forecasts of Biosimilar Insulin in global, including the following market information:
Global Biosimilar Insulin Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Biosimilar Insulin Market Sales, 2017-2022, 2023-2028, (K Unit)
Global top five Biosimilar Insulin companies in 2021 (%)
The global Biosimilar Insulin market was valued at 2632.1 million in 2021 and is projected to reach US$ 6421.8 million by 2028, at a CAGR of 13.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Biosimilar Insulin Glargine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Biosimilar Insulin include Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon and Wockhardt, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Biosimilar Insulin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilar Insulin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Biosimilar Insulin Market Segment Percentages, by Type, 2021 (%)
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Global Biosimilar Insulin Market, by Distribution Channel, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Biosimilar Insulin Market Segment Percentages, by Distribution Channel, 2021 (%)
Hospital
Retail Pharmacy
Others
Global Biosimilar Insulin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Biosimilar Insulin Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilar Insulin revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Biosimilar Insulin revenues share in global market, 2021 (%)
Key companies Biosimilar Insulin sales in global market, 2017-2022 (Estimated), (K Unit)
Key companies Biosimilar Insulin sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt

LEAVE A REPLY

Please enter your comment!
Please enter your name here